Code Snippets
curl "https://financialdata.net/api/v1/employee-count?identifier=BMY&key=API_KEY"import requests
url = 'https://financialdata.net/api/v1/employee-count?identifier=BMY&key=API_KEY'
response = requests.get(url)
print(response.json())
const url = 'https://financialdata.net/api/v1/employee-count?identifier=BMY&key=API_KEY';
const response = await fetch(url);
const data = await response.json();
console.log(data);
Sample Response
[
{
"trading_symbol": "BMY",
"central_index_key": "0000014272",
"registrant_name": "BRISTOL MYERS SQUIBB CO",
"fiscal_year": "2025",
"employee_count": 32500
},
...
]Query Parameters
| Name | Type | Description |
|---|---|---|
| identifier | string | The trading symbol for a security, or the central index key (CIK). The latter is assigned to the entity by the United States Securities and Exchange Commission. (e.g., MSFT, 0000789019) |
| format | string | (Optional) The format of the returned data, either JSON or CSV. Defaults to JSON. (e.g., json, csv) |
Endpoint Overview
This API endpoint returns the total number of company employees for a particular year. The historical data covers several thousand US and international companies.
Company Profile
BRISTOL MYERS SQUIBB CO
NYSE: BMY- Market Cap:$94.19B
- ISIN:US1101221083
- Fiscal Year End:12/31
- CEO:Chris Boerner
- Employees:32500
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States.